← Leaderboards
Lynda Coughlan
Icahn School Of Medicine At Mount Sinai
$2,843,986
Attributed
$2,843,986
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $637.1K · FY2019–25$1M$750K$500K$250K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$2,843,986 · 3
By mechanism
R01$1,952,609 · 1
R21$891,377 · 2
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Viviana A Simon$21,556,427
- Andrew Kasarskis$1,581,602
- Jaime Lynn Hook$2,088,426
- Rebecca Powell$3,892,293
- Patricia Veronica Aguilar$2,319,917
Others in their field
Other Emerging Leaders on “Immunologics”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,577,666
- Kevin Urdahl · Seattle Children'S Hospital$85,664,942
- Yunda Huang · Fred Hutchinson Cancer Center$71,262,090
- Ted Ross · University Of Georgia$68,763,143
- Sarah Fortune · Harvard School Of Public Health$51,119,645
Research focus
ImmunologicsImmuneImmune ResponseImmunogenicityAdjuvantExosomeExtracellular VesiclesEpitopesImmunogenicEnzyme-Linked Immunosorbent AssayAntigen-Specific T CellsAntigen TargetingCesium ChlorideCross ReactivityAdenovirus VectorCytokineB-LymphocytesBronchoalveolar LavageEngineeringImmunityCd8b1 GeneAntigensCellsInnovation
Grant awards (9)
Combining innovative molecular adjuvanting approaches with novel adenoviral vector delivery to generate a universal influenza vaccine$475,336
R01 · FY2025 · AI · contact PI
Combining innovative molecular adjuvanting approaches with novel adenoviral vector delivery to generate a universal influenza vaccine$475,336
R01 · FY2024 · AI · contact PI
Combining innovative molecular adjuvanting approaches with novel adenoviral vector delivery to generate a universal influenza vaccine$475,336
R01 · FY2023 · AI · contact PI
Combining innovative molecular adjuvanting approaches with novel adenoviral vector delivery to generate a universal influenza vaccine$526,601
R01 · FY2022 · AI · contact PI
Exosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectors$420,520
R21 · FY2020 · AI · contact PI
Generation of a polycistronic universal influenza virus vaccine based on rare species adenoviral vectors$192,153
R21 · FY2020 · AI · contact PI
Generation of a polycistronic universal influenza virus vaccine based on rare species adenoviral vectors$19,722
R21 · FY2020 · AI · contact PI
Exosome-display as a strategy to enhance the immunogenicity of SARS-CoV-2 vaccines based on adenoviral vectors$4,732
R21 · FY2020 · AI · contact PI
Generation of a polycistronic universal influenza virus vaccine based on rare species adenoviral vectors$254,250
R21 · FY2019 · AI · contact PI